At this point I would guess it may be undervalued. Just goes down and down and down because I have been watching it for months.
Appears the analysts are extremely on VRTX at this time. That is when I stop and take a closer look sometimes, They could be correct for all I know. Sometimes there are things the big guys know that little guys do not know. Like is VRTX going bankrupt or sumpin? I do not think Cystic Fibrosis is going away as it is a genetic disease, but it is also a primarily Caucasian disease? Perhaps just not socially or politically cool right now since it is a primarily Caucasian disease? Perhaps widening their arena to Sickle Cell anemia research and drugs would help the stock price and the analysts would like the stock/but who knows?/just a thought. Tips appreciated.
Eventually everything hits a highpoint, and everything reaches a low point. The country I live in, has hit a temporary low point.
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG ; Arbor Biotechnologies, Inc. ; Moderna , Inc. ; Genomics plc ; Merck KGaA; Darmstadt, Germany; X-Chem, Inc. ; Janssen Pharmaceuticals, Inc. ; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc. ; Molecular Templates , Inc. ; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.